Health Care · Biological Products, (No Diagnostic Substances)

LXEO Lexeo Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 190710882 filings
Russell 2000

LXEO at a glance

Lexeo Therapeutics, Inc. (LXEO, SEC CIK 1907108) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Lexeo Therapeutics, Inc. (LXEO) shares worth $111.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Townsend Richard Nolan on November 17, 2026 of 3,295 shares at $3.26 per share.
  • In the last 90 days, LXEO insiders reported 0 open-market purchases ($0) and 3 open-market sales ($18K) on Form 4, a net sale of $18K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 3 sells
Net −$18K
13F holders
28 funds
$111.6M · +2 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 8.01 · Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales generated
  • Net loss $38.3M vs $20.3M YoY, operating loss $40.4M vs $21.6M
  • LX2006 R&D $12.7M vs $5.1M, best-performing program by quarterly spending
  • Cash, equivalents and Treasury investments $219.1M vs $246.6M at year-end; operating cash outflow $67.3M
  • Management expects funding into 2028, with continued losses and significantly higher development expenses ahead

Risk Factors

  • Newly added regulatory risk: 2026 legislation codified orphan exclusivity by approved indication and extended pediatric priority vouchers only through September 30, 2029
  • Most materially updated FDA risk: agency reorganization, potential shutdowns, layoffs, and resource constraints could delay reviews, approvals, and inspections
  • Clinical safety risk: LX2006 preclinical studies observed four hepatocellular carcinomas in wild-type mice 10 months after treatment
  • Competitive risk: LX2006 faces Solid Biosciences, Voyager-Neurocrine, Larimar, Design Therapeutics, and PTC Therapeutics programs
  • Liquidity risk: $219.1 million in cash, cash equivalents, and U.S. Treasury investments expected to fund operations into 2028

AI summary of the LXEO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 8.01: Other Events

  • Positive interim Phase I/II data announced for LX2020 targeting PKP2-associated arrhythmogenic cardiomyopathy
  • Regulatory updates for LX2020 create potential development-pathway implications

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Lexeo’s business highlights and financial results for the three and nine months ended September 30, 2026
  • Investors should review Exhibit 99.1 for earnings figures, cash position, pipeline updates and forward operating implications

Item 7.01: Regulation FD Disclosure

  • Corporate presentation attached as Exhibit 99.2 for the referenced webcast
  • Investor relevance depends on pipeline, clinical, regulatory, or financing updates in the presentation

Item EX-99.3: Item EX-99.3

  • Corporate overview highlights LX2006 as Lexeo’s lead FA-cardiomyopathy asset, with potential first disease-modifying gene therapy in a high-unmet-need market
  • SUNRISE-FA 2 pivotal study initiated June 2026, enrolling 26 participants with 13 treated at 1.2×10¹² vg/kg

Item EX-99.1: Item EX-99.1

  • High-dose LX2020 cohorts showed 80% mean NSVT reduction and 44% mean PVC reduction at latest assessment, supporting clinical proof-of-concept
  • FDA openness to NSVT as a primary surrogate endpoint strengthens potential accelerated-approval pathway, with pivotal design expected in 1H 2027

Item EX-99.2: Item EX-99.2

  • Phase 1/2 HEROIC-PKP2 interim data: high-dose LX2020 reduced mean NSVT 80% and PVC burden 44% at latest assessment, n=7
  • Five of seven high-dose participants reported symptom improvement, while cardiac MRI showed stabilization or improvement in most participants
Filed Sep 29, 2026Full analysis →

Item 3.02: Unregistered Sales of Equity Securities

  • Common Stock issued in the Merger, creating potential dilution for existing Lexeo shareholders
  • Shares issued without Securities Act registration under Section 4(a)(2) and/or Regulation D exemptions

Item 2.01: Completion of Acquisition or Disposition of Assets

  • Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo shares, subject to closing adjustments
  • Up to $1.0M additional cash contingent on specified events, creating potential future acquisition cost
Filed Sep 22, 2026Full analysis →

Item 8.01: Other Events

  • Merger Agreement with Mantle Therapeutics and strategic collaborations mark a potentially transformative corporate development
  • Expected merger closing and contingent consideration remain subject to conditions and execution risks

Item 1.01: Entry into a Material Definitive Agreement

  • Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo stock, subject to adjustments
  • Up to $13.0M additional contingent consideration, including $1.0M cash and $12.0M milestone payments over 12 years

Item EX-99.1: Item EX-99.1

  • Mantle acquisition adds four FA programs across oral, protein-replacement, and ASO modalities for $8.3M upfront
  • Potential consideration reaches $21.3M, including $13.0M in success-based milestones

Item EX-99.2: Item EX-99.2

  • Mantle acquisition adds four FA programs spanning oral, protein-replacement and RNA approaches, broadening Lexeo beyond LX2006’s cardiac focus
  • Upfront consideration $8.3M, with success-based milestones up to $13M, payable in cash and equity

AI summaries of LXEO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LXEO

Don't miss the next LXEO filing

  • Alerts as it files. A push when LXEO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LXEO, by share count.
  • Ask anything. An AI agent that reads every LXEO filing and answers with sources.

LXEO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Townsend Richard NolanSellNov 17, 2026$3.26
Tamayo Louis EdwardSellNov 17, 2026$3.26
Otero Jose ManuelSellNov 17, 2026$3.26
Schilke TobinANov 14, 2026-
Bhalla Narinder PalASep 24, 2026-
Townsend Richard NolanASep 24, 2026-
Otero Jose ManuelASep 24, 2026-
Tamayo Louis EdwardASep 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$68.5M-$105.8M-$109.3M
Net Income-$66.4M-$98.3M-$100.0M
Balance Sheet
Total Assets$139.8M$146.9M$268.7M
Equity-$116.8M$246.7M
ROE--84.2%-40.5%
Per Share
EPS$-12.40$-3.09$-1.86
Cash Flow
Operating CF-$59.5M-$81.2M-$98.6M
CapEx$115K$481K$397K

Source: XBRL data in Lexeo Therapeutics, Inc. (LXEO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LXEO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LXEO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$111.6M
Q2 202626$130.5M
Q1 202625$138.0M
Q4 202526$223.1M
Q3 202523$95.8M
Q2 202520$51.5M
Q1 202517$24.7M
Q4 202411$38.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 176 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LXEO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 17, 2026--
8-KNov 16, 2026Analysis-
10-QNov 16, 2026Analysis
8-KSep 29, 2026Analysis-
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
4Sep 28, 2026--
8-KSep 22, 2026Analysis-
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
SC 13GAug 14, 2026-
10-QAug 12, 2026Analysis
8-KAug 12, 2026Analysis-
SC 13GAug 7, 2026-
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jun 29, 2026--
8-KJun 29, 2026Analysis-

Related Health Care companies

All Health Care →

LXEO SEC filings: frequently asked questions

Are LXEO insiders buying or selling?

In the last 90 days, Lexeo Therapeutics, Inc. (LXEO) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $18,214 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LXEO stock?

As of September 30, 2026, the largest Lexeo Therapeutics, Inc. (LXEO) holders among the 13F filers tracked by SignalX were BlackRock ($20.2 million), JPMorgan Chase & Co ($15.7 million), Citadel Advisors LLC ($14.3 million), Millennium Management ($12.8 million), State Street Corp ($12.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did LXEO report in its latest 8-K?

Lexeo Therapeutics, Inc. (LXEO) filed an 8-K on November 16, 2026 reporting Item 8.01 (Other Events), Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Positive interim Phase I/II data announced for LX2020 targeting PKP2-associated arrhythmogenic cardiomyopathy.

What are the latest LXEO SEC filings?

Lexeo Therapeutics, Inc. (LXEO) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.

What is LXEO's SEC CIK number?

Lexeo Therapeutics, Inc. (LXEO)'s SEC Central Index Key (CIK) is 1907108. EDGAR lists every LXEO filing under that number.

Ask anything about LXEO

The research agent reads LXEO's filings, financials, insider trades and 13F holders, then answers with sources.